American Century Companies Inc. Buys 27,650 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• American Century Companies Inc. increased its stake in Jazz Pharmaceuticals by 17.2% during the first quarter, now owning approximately $23.3 million worth of shares.
• Jazz Pharmaceuticals reported earnings of ($8.25) per share, falling short of analysts' estimates, while quarterly revenue saw a slight increase of 2.1% year-over-year.
• Thirteen research analysts have rated Jazz Pharmaceuticals with a Buy rating, and the company has a consensus price target of $181.43.

American Century Companies Inc. raised its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 17.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 188,062 shares of the specialty pharmaceutical company's stock after buying an additional 27,650 shares during the quarter. American Century Companies Inc. owned 0.31% of Jazz Pharmaceuticals worth $23,348,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Hurley Capital LLC acquired a new position in Jazz Pharmaceuticals in the 1st quarter valued at approximately $25,000. Elequin Capital LP increased its stake in Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after buying an additional 183 shares during the period. Parallel Advisors LLC increased its stake in Jazz Pharmaceuticals by 85.6% in the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after buying an additional 119 shares during the period. Spire Wealth Management increased its stake in Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after buying an additional 161 shares during the period. Finally, Picton Mahoney Asset Management increased its stake in Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after buying an additional 269 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $1.48 during trading hours on Friday, hitting $127.61. 103,359 shares of the stock were exchanged, compared to its average volume of 946,990. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The company's 50 day moving average is $114.07 and its 200 day moving average is $117.25. The firm has a market capitalization of $7.74 billion, a P/E ratio of -18.92, a P/E/G ratio of 7.84 and a beta of 0.34. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.Jazz Pharmaceuticals's quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the company posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the sale, the chief executive officer directly owned 436,973 shares of the company's stock, valued at $47,031,403.99. This represents a 0.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on JAZZ shares. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday. Truist Financial upped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research note on Thursday. Robert W. Baird dropped their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Morgan Stanley increased their price target on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target on the stock. Thirteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $178.21.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.